Samuraciclib is under clinical development by Carrick Therapeutics and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Samuraciclib’s likelihood of approval (LoA) and phase transition for Breast Cancer took place on 05 Dec 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 05 Dec 2022 decreased Samuraciclib’s LoA and PTSR for Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, and decreased LoA and PTSR for Triple-Negative Breast Cancer (TNBC).

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Samuraciclib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Samuraciclib overview

Samuraciclib (CT-7001) is under development for the treatment of triple negative breast cancer, metastatic or locally advanced HR+ and HER2- breast cancer, colorectal cancer, ovarian cancer, prostate cancer, acute myeloid leukemia and small-cell lung cancer. It is administered through the oral route. The drug candidate acts by targeting cyclin-dependent kinase 7 (CDK7).

Carrick Therapeutics overview

Carrick Therapeutics is a biopharmaceutical company that focuses on the research and development of cancer therapies. The company develops drugs that target the molecular pathways of the most aggressive and resistant forms of cancer. In addition, Carrick Therapeutics strives to advance its programs by comprehending the cancer-causing mechanisms and combining them with the latest technologies to identify treatments. It works in collaboration with a cancer research charity, Cancer Research UK, and academic institutions such as Cambridge University, Oxford University, and Imperial College, to discover and develop cancer medicines. The company has a presence in Ireland and the UK. Carrick Therapeutics is headquartered in Dublin, Ireland.

Quick View Samuraciclib LOA Data

Report Segments
  • Innovator
Drug Name
  • Samuraciclib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.